top of page

Meet Our Team


Christophe Tournerie, MD
Founder, CEO

Dr. Tournerie is the Founder and Chief Executive Officer of ClinActis. He has more than 25 years of experience in clinical research in Europe and Asia Pacific including Japan, working with biotechnology companies, pharmaceutical companies and clinical research organizations.

After completion of his medical studies in Paris and various hospital assignments in France, Dr. Tournerie spent 3 years at the National Medical Research Institute in France in the field of drug development in anti-HIV products. His introduction to the pharmaceutical industry was as Medical Director in an American biotechnology company developing anti-HIV products. Then, he moved to a large global CRO, heading the Project management Department for South Europe, and then as Head of Operations in the Japan affiliate.

Later, Dr. Tournerie headed the Asian clinical research activity for a multi-national Pharmaceutical Company, based in Singapore.

More recently, Dr. Tournerie was Vice President Asia Pacific for a large global CRO, based in Singapore. During this assignment, Dr. Tournerie developed the business strategy for the region, successfully established and directed operations in 12 countries and built a highly professional team.

Sharon Ng joins ClinActis with more than 20 years of experience in health science and clinical research with 10 years project management and clinical monitoring experience in large global/multi-national studies (Phase I, II, III, IV) across Asia-Pacific as well as line management of Project Managers, Clinical Research Associates & Project Specialist. Her therapeutic experience is in Oncology, CNS, Cardiovascular, Respiratory and Diabetes. She also has 5 years’ experience in quality management roles, being responsible with updating and maintaining the Clinical Development Quality System, as well as involved in identifying and implementing initiatives relating to quality improvement at the project, client, department, or cross department level as well as being responsible for the maintenance of the training matrix for Clinical Development.

Sharon Ng 1.jpg
Sharon NG
Clinical Operations, Director
Imen Jelassi, PharmD, MSc
EU Director Strategic Relations

Imen Jelassi is pharmacist with 8 years experience and a good knowledge of the pharma sphere including pharmaceutical companies, biotechs, medical device companies and CROs. She has both scientific and sales background with a competency in Marketing.

She has significant experience in business development for both products and services and has initiated prospection activities in Europe and also in LATAM and Russia for her clients. She has performed Business Development activities for both human and veterinary products. Due to her skills and experience, she is able to target the right prospects for her clients based on her deep knowledge of the market and a focus on her client’s needs.

Imen past experiences include being a CRA who possess a good understanding of GCP, the conduct of clinical trials, the regulation and feasibility studies in Europe and the MENA region.

Imen also holds a master degree in health marketing and has the right competencies for conducting market studies, market intelligence, market access, competitor analysis, increasing brand exposure and multichannel marketing.

Imen is based in Paris, France and speaks 4 languages: English, French, German and Arabic.

Bill came to ClinActis with over 40 years of Clinical and Pharmaceutical experience. Bill was one of the pioneers in the CRO industry as a founder of the largest late stage CRO, In Vivo, Inc. that he grew to over 300 people and offices on three continents.

After selling In Vivo, he became President of the Clinical Division of Dendrite International, helping launch their global EDC and Safety support helpdesk. Mr. Van Nostrand went on to lead the clinical division of FCG before becoming the Chief Business Officer for The Copernicus Group IRB. Most recently, Bill served as EVP and head of Business Development for WCCT Global, a leading Phase 1-4 CRO with one of the largest Clinical Pharmacology units in the U.S.

Bill Van Nostrand
Business Development Head,  North America
bottom of page